US FDA approves Pfizer booster for 12-15-year olds

Monday, 03. January 2022 15:58

United States Food and Drug Administration (FDA) on Monday expanded the eligibility for the booster dose of the Pfizer Inc.-BioNTech SE COVID-19 vaccine to children aged 12 to 15, under the emergency use authorization (EUA).

The FDA also shortened the timespan between the primary vaccination regime and the booster to five months for the Pfizer-BioNTech shot. In addition, the third vaccine has been authorized for certain immunocompromised children aged 5 to 11.

"Throughout the pandemic, as the virus that causes COVID-19 has continuously evolved, the need for the FDA to quickly adapt has meant using the best available science to make informed decisions with the health and safety of the American public in mind," Acting FDA Commissioner Janet Woodcock noted in a statement.

Related Links: BioNTech SEPfizer Inc.
Baha Breaking the News (BBN) / MS